We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.38%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.47B
AUM Growth
+$39M
Cap. Flow
-$32.3M
Cap. Flow %
-2.19%
Top 10 Hldgs %
26.19%
Holding
101
New
9
Increased
29
Reduced
33
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$21.4M
2
PFE icon
Pfizer
PFE
+$19.4M
3
VEEV icon
Veeva Systems
VEEV
+$17.8M
4
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$11.9M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$11.6M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13M
3
LIVN icon
LivaNova
LIVN
+$11.9M
4
NVCR icon
NovoCure
NVCR
+$11.7M
5
CNC icon
Centene
CNC
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 94.98%
2 Industrials 1.94%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
26
Guardant Health
GH
$22.6B
$21.7M 1.48%
175,000
-50,000
-22% -$6.73M
ISRG icon
27
Intuitive Surgical
ISRG
$134B
$20.7M 1.4%
67,500
-19,500
-22% -$5.47M
GILD icon
28
Gilead Sciences
GILD
$165B
$20.7M 1.4%
300,000
-50,000
-14% -$3.34M
INOV
29
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
$20.4M 1.39%
600,000
+385,000
+179% +$11.9M
ABMD
30
DELISTED
Abiomed Inc
ABMD
$20.3M 1.38%
65,000
-13,000
-17% -$3.99M
COR icon
31
Cencora
COR
$61.2B
$19.8M 1.34%
173,000
+5,043
+3% +$596K
PFE icon
32
Pfizer
PFE
$153B
$19.6M 1.33%
+500,000
New +$19.4M
BHVN
33
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$19.5M 1.32%
200,419
– –
APLS
34
DELISTED
Apellis Pharmaceuticals
APLS
$19.3M 1.31%
305,000
+35,000
+13% +$1.81M
EXAS
35
DELISTED
Exact Sciences
EXAS
$19.3M 1.31%
155,000
-20,000
-11% -$2.39M
CNC icon
36
Centene
CNC
$32.5B
$19M 1.29%
260,000
-160,000
-38% -$11M
COO icon
37
Cooper Companies
COO
$14.5B
$17.8M 1.21%
180,000
-20,000
-10% -$1.96M
ITCI
38
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$17.5M 1.19%
429,728
-28,050
-6% -$1.04M
NKTR icon
39
Nektar Therapeutics
NKTR
$2.58B
$16.3M 1.11%
63,333
-23,813
-27% -$6.59M
ACCD
40
DELISTED
Accolade Inc
ACCD
$16.3M 1.11%
300,000
+100,000
+50% +$4.86M
PHR icon
41
Phreesia
PHR
$773M
$15.9M 1.08%
260,000
+200,000
+333% +$10.4M
HCA icon
42
HCA Healthcare
HCA
$89.5B
$15.5M 1.05%
75,000
– –
MCK icon
43
McKesson
MCK
$101B
$14.9M 1.01%
78,000
-10,000
-11% -$1.93M
MGNX icon
44
MacroGenics
MGNX
$257M
$14.6M 0.99%
545,160
– –
REGN icon
45
Regeneron Pharmaceuticals
REGN
$80.8B
$14M 0.95%
25,000
+5,000
+25% +$2.53M
BMRN icon
46
BioMarin Pharmaceuticals
BMRN
$12.4B
$13.3M 0.91%
160,000
-20,000
-11% -$1.59M
HCAT icon
47
Health Catalyst
HCAT
$128M
$13.3M 0.9%
240,000
+125,000
+109% +$6.66M
JNJ icon
48
Johnson & Johnson
JNJ
$625B
$12.4M 0.84%
75,000
-250,000
-77% -$41.4M
RCM
49
DELISTED
R1 RCM Inc. Common Stock
RCM
$12.2M 0.83%
550,000
+350,000
+175% +$8.45M
ESPR
50
DELISTED
Esperion Therapeutics
ESPR
$12.1M 0.82%
572,267
-19,958
-3% -$481K
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rhenman & Partners Asset Management held 101 positions worth $1.47B, up 2.7% from $1.43B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management's Q2 2021 filing shows 9 new, 29 increased, 33 reduced and 7 closed positions. Its largest new stake was Pfizer: 500,000 shares worth $19.6M. The largest sale was Johnson & Johnson, an estimated $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Rhenman & Partners Asset Management's largest Q2 2021 buy was Pfizer: 500,000 shares worth $19.6M.
  • Rhenman & Partners Asset Management added most to Biogen in Q2 2021, an estimated $21.4M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2021 reduction was Johnson & Johnson, cutting an estimated $41.4M.
  • Rhenman & Partners Asset Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $6.41M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $1.47B portfolio in Q2 2021.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 7 in Q2 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 2.7% quarter-over-quarter to $1.47B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.